Loading…

SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK

Saved in:

Bibliographic Details
Published in:	Hematological oncology 2021-06, Vol.39 (S2)
Main Authors:	Novak, U., Fehr, M., Schär, S., Dreyling, M., Scheubeck, G., Ramadan, S., Zucca, E., Zander, T., Hess, G., Mey, U., Ferrero, S., Mach, N., Boccomini, C., Böttcher, S., Voegeli, M., Cairoli, A., Menter, T., Dirnhofer, S., Gadient, S., Eckhardt, K., Driessen, C., Renner, C.
Format:	Article
Language:	English
Subjects:	Bortezomib Lymphoma Mantle cell lymphoma Targeted cancer therapy
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!